H.R. 1492

119th Congress

In Committee

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Sponsored byRepublican:Rep. Murphy, Gregory F. [R-NC-3]NC· Introduced 21 février 2025
Open on Congress.gov

68

Cosponsors

4

Actions

0

Amendments

2

Committees

—

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

21 février 2025·1 year ago

Summary

Introduced in House · Updated 22 septembre 2025

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. 

The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation.

The bill's changes apply retroactively.

Timeline

4 actions

  1. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    21 février 2025 · IntroReferral

  2. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    21 février 2025 · IntroReferral

  3. Introduced in House

    21 février 2025 · IntroReferral

  4. Introduced in House

    21 février 2025 · IntroReferral

Sponsorship

68 cosponsors

Sponsor

Republican:Rep. Murphy, Gregory F. [R-NC-3]NC

Cosponsors

  • Democrat36%
  • Republican4794%
View all on Congress.gov

Classification

Policy area

Health

Legislative subjects

Health care costs and insuranceMedicarePrescription drugs

Committees

2

  • Energy and Commerce Committee

    House · Standing

    • Referred To21 Feb 2025

  • Ways and Means Committee

    House · Standing

    • Referred To21 Feb 2025
Pelosi Tracker
Follow on XRejoignez notre Discord
PolitiquesProjets de loiPortefeuillesTarifsÀ proposMentions légalesConditions d'utilisationPolitique de confidentialité
English
© 2026 - Tous droits réservés. Propulsé par Vantara Labs
Ce site web est une plateforme indépendante et tierce. Il n'est pas affilié à, approuvé par ou associé de quelque manière que ce soit à Nancy Pelosi, son bureau ou ses représentants. Toute utilisation de son nom est uniquement à des fins de discussion d'informations publiques disponibles.Les informations fournies sur ce site web sont uniquement à des fins informatives et éducatives et ne sont pas destinées à servir de conseils financiers ou d'investissement, ni ne doivent être interprétées comme tels. Les données présentées ici proviennent de déclarations et dossiers publics. Bien que nous nous efforcions d'assurer l'exactitude, l'actualité et l'exhaustivité, nous ne garantissons pas que toutes les informations sont exemptes d'erreurs ou à jour.Le support est disponible en anglais. Certaines traductions sont automatiques.